128 related articles for article (PubMed ID: 3502618)
1. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.
Hertler AA; Spitler LE; Frankel AE
Cancer Drug Deliv; 1987; 4(4):245-53. PubMed ID: 3502618
[TBL] [Abstract][Full Text] [Related]
2. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE
Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma.
Selvaggi K; Saria EA; Schwartz R; Vlock DR; Ackerman S; Wedel N; Kirkwood JM; Jones H; Ernstoff MS
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):201-7. PubMed ID: 8471594
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.
Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW
Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738
[TBL] [Abstract][Full Text] [Related]
5. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
6. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
Spitler LE; del Rio M; Khentigan A; Wedel NI; Brophy NA; Miller LL; Harkonen WS; Rosendorf LL; Lee HM; Mischak RP
Cancer Res; 1987 Mar; 47(6):1717-23. PubMed ID: 3493066
[TBL] [Abstract][Full Text] [Related]
7. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
Kornfeld SB; Leonard JE; Mullen MD; Taetle R
Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
9. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
J Biol Response Mod; 1990 Aug; 9(4):345-54. PubMed ID: 2395000
[TBL] [Abstract][Full Text] [Related]
10. Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.
Byers VS; Austin EB; Clegg JA; Denton G; Gunn B; Hooi D; Hudecz F; Price MR; Baldwin RW
J Clin Immunol; 1993 Nov; 13(6):406-14. PubMed ID: 7507127
[TBL] [Abstract][Full Text] [Related]
11. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
13. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.
Chiron M; Jaffrezou JP; Carayon P; Bordier C; Roubinet F; Xavier C; Brandely M; Laurent G
Clin Exp Immunol; 1990 Nov; 82(2):214-20. PubMed ID: 2122930
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
15. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.
Hertler AA; Schlossman DM; Borowitz MJ; Blythman HE; Casellas P; Frankel AE
Int J Cancer; 1989 Feb; 43(2):215-9. PubMed ID: 2465276
[TBL] [Abstract][Full Text] [Related]
16. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
[TBL] [Abstract][Full Text] [Related]
18. Effect of cyclophosphamide on the immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.
Harkonen S; Mischak R; Lopez H; Stoudemire J
Cancer Drug Deliv; 1987; 4(3):151-7. PubMed ID: 3502453
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.
Harkonen S; Stoudemire J; Mischak R; Spitler LE; Lopez H; Scannon P
Cancer Res; 1987 Mar; 47(5):1377-82. PubMed ID: 3493064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]